20
Participants
Start Date
March 31, 2026
Primary Completion Date
December 31, 2027
Study Completion Date
May 31, 2031
Depletion of CD3/CD19 in an autologous stem cell transplant
The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
Stephan Grupp MD PhD
OTHER